AstraZeneca third-line lung cancer combination study fails

LONDON (Reuters) - A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping patients live longer.

from Reuters: Health News https://ift.tt/2JjzWem
via IFTTT